

KYBORA helps Symbiomix raise \$35M Series A from Orbimed and F-Prime



\$35M EQUITY FINANCING



OrbiMed
Healthcare Fund Management

The Challenge

The entrepreneur that created Symbiomix needed to raise capital to realize his vision. This required the preparation of all needed marketing material needed to go to market and identifying investors willing to invest in a differentiated infectious disease compound.

The Solution

KYBORA analyzed the situation, prepared all the marketing material including teaser, non-conf, confidential info memo, and a virtual data room, performed a valuation to help with future funding negotiations, identified about 120 potential investors and systematically reached out to them to gauge their level of interest. Once a lead was identified, KYBORA worked with the founder to help identify co-investors to form a syndicate.

The Outcome

Symbiomix raised \$35M from Orbimed and F-Prime and used those proceeds to successfully receive an FDA approval in 2017.

KYBORA's mission is to guide transformative healthcare companies to enduring success globally. We provide M&A, Licensing, Fundraising and Strategic Advisory services to the global Biopharma industry, creating value for our Clients worldwide.

To learn more, please reach out to us at

info@kybora.com

kybora.com

